Article

Transpupillary thermotherapy has high success rate with choroidal melanomas

Rochester, MN-Transpupillary thermotherapy (TTT) caused small choroidal melanoma tumors to regress in most of the patients who were treated with this diode laser therapy. In a study of 40 patients, almost 80% of patients were successfully treated with one application of TTT. Additional therapy with TTT and other modalities was needed to treat some cases of small choroidal melanomas.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Related Content
More companies announce ARVO 2025 presentations
May 2nd 2025

More companies announce ARVO 2025 presentations

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Retinal thinning may serve as early biomarker of genetic risk for schizophrenia
May 2nd 2025

Retinal thinning may serve as early biomarker of genetic risk for schizophrenia

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

ZEISS unveils new AI-driven research data platform
May 2nd 2025

ZEISS unveils new AI-driven research data platform

OcuMet Beacon granted clearance by FDA
May 1st 2025

OcuMet Beacon granted clearance by FDA

© 2025 MJH Life Sciences

All rights reserved.